

REMARKS

I. THE REJECTIONS UNDER 35 U.S.C. § 112, 1st ¶

The Office Action rejects claims 1 and 3 under 35 U.S.C. § 112, first paragraph, for use of the term “prodrug”. In response, Applicants submit that the amendment to claims 1 and 3 obviates any basis for the rejection of these claims. Reconsideration and withdrawal of the rejection of claims 1 and 3 under 35 U.S.C. § 112, first paragraph, are respectfully requested.

The Office Action rejects claim 23 under 35 U.S.C. § 112, first paragraph. In response, Applicants submit that the cancellation of claim 23 obviates any basis for the rejection of this claim. Reconsideration and withdrawal of the rejection of claim 23 under 35 U.S.C. § 112, first paragraph, are respectfully requested.

II. THE REJECTION UNDER 35 U.S.C. § 103

The Office Action rejects claims 1, 3, 6-8 and 19-23 under 35 U.S.C. § 103 as being obvious over WO03016306 as evidenced by Clercq, Il Farmaco, 54 (1999) 25-45, in view of Peiperi et al., Tenofovir (Viread, PMPA), August 7, 2003.

In response, Applicants submit that the cited references do not disclose or suggest the combination as presently claimed. Reconsideration and withdrawal of the rejection of claims 1, 3, 6-8 and 19-23 under 35 U.S.C. § 103 over WO03016306 and Clercq45, in view of Peiperi et al. are respectfully requested.

III. CONCLUSION

Early consideration and prompt allowance of the claims are respectfully requested.

Respectfully submitted,

/Laura A. Donnelly/

By: _____
Laura A. Donnelly
Reg. No. 38,435

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1729
Dated: February 12, 2009